Tag: @EliLillyandCo

Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds

A sub-group analysis of the ATTAIN-1 and ATTAIN-2 trials finds that orforglipron produced significant reductions in body weight and HbA1c in adults aged 65 and older, with a safety profile consistent with younger populations.

WeightControl.com Interview with:
Deborah B. Horn, DO, MPH, FOMA
Medical Director for Center of Obesity Medicine and Metabolic Performance
McGovern Medical School
UTHealth Houston, Texas

A new sub-group analysis of two major clinical trials examines how the oral GLP-1 medication orforglipron performs in adults aged 65 and older — with encouraging findings on both efficacy and safety. Continue reading “Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds”

Patients Who Stopped Tirzepatide (Mounjaro™) For Weight Control Gradually Regained Most of Lost Weight 

Obesity is a chronic disease, like diabetes and hypertension. If treatment is discontinued, it will relapse, though gradually.

WeightControl.com Interview with:
Louis J Aronne M.D.
Sanford I. Weill Professor of Metabolic Research
Department of Medicine
Weill Cornell Medicine

WeightControl.com:  What is the background for this study? What are the main findings?

Response: The SURMOUNT -4 trial demonstrates that patients who discontinued tirzepatide after losing 20.9% over 36 weeks regained about half the weight in one year to an average 9.5% weight loss following discontinuation while those who continued lost an additional 5%.  

The metabolic parameters which had improved with weight loss returned towards their starting point, but did not completely regress.  

Continue reading “Patients Who Stopped Tirzepatide (Mounjaro™) For Weight Control Gradually Regained Most of Lost Weight “